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Purpose: To report the effective treatment of radiation macular edema following ruthenium-
106 plaque brachytherapy for a choroidal melanoma with a dexamethasone 0.7-mg 
(Ozurdex®) intravitreal implant.  
Methods: An interventional case report with optical coherence tomography (OCT) scans.  
Results: A 65-year-old Caucasian woman was suffering from radiation macular edema 
following ruthenium-106 plaque brachytherapy for a choroidal melanoma on her left eye. 
She had undergone one intravitreal injection of 0.5 mg bevacizumab (Avastin®, 
Genentech/Roche) in the following months without functional or anatomical improvement. 
Seven months after the development of radiation macular edema, she received a single 
intravitreal injection of dexamethasone 0.7 mg (Ozurdex). Four weeks following the 
injection, her best-corrected visual acuity improved from 0.3 to 0.5. Radiation macular 
edema resolved with a reduction of central retinal thickness from 498 μm before Ozurdex 
injection to 224 μm after Ozurdex injection, as measured by OCT scan.  
Conclusion: Dexamethasone 0.7 mg (Ozurdex) has proven to be an effective treatment 
option in retinal vein occlusion and noninfectious uveitis. It can also be considered as off-
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label treatment in radiation macular edema following ruthenium-106 plaque brachytherapy 
for a choroidal melanoma. 
 
Introduction 
Radiation retinopathy is a predictable complication after radioactive scleral plaque 
application for treatment of intraocular tumors, most commonly choroidal melanoma 
[1]. Macular edema is a common manifestation of radiation retinopathy that may lead 
to severe visual loss. According to Guyer et al. [2], it was the most frequent and early 
finding after proton beam therapy for paramacular choroidal tumors, with 87% of 218 
patients who developed macular edema. Other studies suggest rates of radiation 
maculopathy from plaque radiotherapy of 18% [3], 23% [4], and 42.8% [5]. Different 
treatment modalities for macular edema have been reported. These include laser 
photocoagulation [6], photodynamic therapy [7], pentoxifylline [8] and intravitreal 
bevacizumab [9, 10]. 
Corticosteroids are potent anti-inflammatory agents that can counteract many of the 
pathological processes thought to play a role in the development of macular edema. 
Recently, a sustained-release dexamethasone implant (Ozurdex®) proved to be effective 
for the treatment of macular edema secondary to a variety of underlying diseases with 
a potentially lower rate of adverse events [11]. 
There are no cases of radiation macular edema after ruthenium (Ru)-106 plaque 
brachytherapy for choroidal melanoma resolved by an intravitreal dexamethasone 0.7-
mg implant described so far in the literature. 
We report a case of radiation macular edema after Ru-106 brachytherapy for a 
choroidal melanoma, refractory to a previous treatment with intravitreal bevacizumab, 
and resolved with significant improvement of visual function following an intravitreal 
injection of dexamethasone 0.7 mg. 
Case Report 
A 65-year-old Caucasian woman developed radiation macular edema 24 months following Ru-106 
plaque brachytherapy for a choroidal melanoma on her left eye (fig. 1a). She underwent one 
intravitreal injection of 0.5 mg bevacizumab (Avastin®, Genentech/Roche) in the following months 
without functional or anatomical improvement. Seven months after the development of radiation 
macular edema, she received a single intravitreal injection of dexamethasone 0.7 mg (Ozurdex) as off-
label treatment. Four weeks following the injection, her best-corrected visual acuity (BCVA) improved 
from 0.3 to 0.5. The radiation macular edema resolved (fig. 1b) with a reduction of central retinal 
thickness from 498 μm before Ozurdex injection (fig. 2a) to 224 μm after Ozurdex injection (fig. 2b), 
as measured by optical coherence tomography (OCT) scan. Her condition has been stable for at least 5 
months now, as seen on the last examination, with BCVA 0.6 and resolved macular edema in the 
treated eye. No complications were observed. 
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Shields et al. [12] reported the use of intravitreal triamcinolone (4 mg/ml) in a 
prospective, nonrandomized, single-center case series of 31 patients with visually 
symptomatic radiation-induced macular edema after plaque radiotherapy. They 
reported that visual acuity was stable or improved in 91% of patients by one month 
and 45% by six months; they also found a decrease in the mean central subfield foveal 
thickness measured by OCT. Despite the potential benefits, intravitreal injection of 
triamcinolone acetate is associated with side effects, including glaucoma, cataracts, 
retinal detachment, and endophthalmitis [13, 14]. 
Also intravitreal bevacizumab has been evaluated as a treatment option for radiation 
maculopathy secondary to plaque radiotherapy [9, 10]. Our patient was initially treated 
with an intravitreal injection of bevacizumab which has not proved effective. Gupta et 
al. [9] stated that intravitreal injection of bevacizumab for treatment of radiation 
maculopathy caused by plaque radiotherapy was not useful for long-standing macular 
edema or when direct irradiation was received by the fovea. 
One of the main mechanisms of the chronic macular edema is the alteration of Muller 
cells functionality; it has been experimentally shown that steroids, by reducing the 
osmotic swelling of the Muller’s cells, improve their functionality and reduce the 
macular edema [15]. 
This could indicate that dexamethasone implant (Ozurdex) might be an effective 
treatment option not only in retinal vein occlusion and noninfectious uveitis, but can 
also be considered as off-label treatment in radiation macular edema after Ru-106 
plaque brachytherapy for choroidal melanoma. 
Disclosure Statement 







Case Rep Ophthalmol 2012;3:71–76 
DOI: 10.1159/000337144 
Published online: 
February 25, 2012 








Fig. 1. a Fluorescein angiography before Ozurdex injection. b Fluorescein angiography four weeks 
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Fig. 2. a OCT before Ozurdex injection; central retinal thickness was 498 μm. b OCT four weeks after 
the injection of Ozurdex; central retinal thickness was 224 μm. 
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